Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
STOK 
Stoke Therapeutics Inc (STOK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: STOK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $22.38
1 Year Target Price $22.38
| 7 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -20.29% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 636.05M USD | Price to earnings Ratio 13.87 | 1Y Target Price 22.38 |
Price to earnings Ratio 13.87 | 1Y Target Price 22.38 | ||
Volume (30-day avg) 10 | Beta 1.1 | 52 Weeks Range 5.35 - 16.15 | Updated Date 07/2/2025 |
52 Weeks Range 5.35 - 16.15 | Updated Date 07/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.84 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 26.33% | Operating Margin (TTM) 70.15% |
Management Effectiveness
Return on Assets (TTM) 7.81% | Return on Equity (TTM) 20.5% |
Valuation
Trailing PE 13.87 | Forward PE - | Enterprise Value 264702087 | Price to Sales(TTM) 3.33 |
Enterprise Value 264702087 | Price to Sales(TTM) 3.33 | ||
Enterprise Value to Revenue 1.39 | Enterprise Value to EBITDA 6.56 | Shares Outstanding 54596900 | Shares Floating 38779649 |
Shares Outstanding 54596900 | Shares Floating 38779649 | ||
Percent Insiders 4.58 | Percent Institutions 110.87 |
Analyst Ratings
Rating 3 | Target Price 22.38 | Buy 2 | Strong Buy 7 |
Buy 2 | Strong Buy 7 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Stoke Therapeutics Inc
Company Overview
History and Background
Stoke Therapeutics Inc. was founded in 2014. The company focuses on developing antisense oligonucleotide (ASO) medicines to treat severe genetic diseases by upregulating protein expression. They went public in 2019. Significant milestones include advancing their lead candidate, STK-001, into clinical trials for Dravet syndrome and developing their TANGO platform for identifying druggable targets.
Core Business Areas
- RNA-Targeting Medicines: Focuses on developing RNA-targeting therapies to address the underlying cause of genetic diseases.
- TANGO Platform: Utilizes its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to identify and validate targets for ASO-mediated upregulation.
- Clinical Development: Conducts clinical trials to evaluate the safety and efficacy of its therapeutic candidates.
Leadership and Structure
The leadership team is headed by Edward M. Kaye, MD, as CEO. The company has a scientific advisory board with experts in RNA biology and drug development. Stoke is structured with departments dedicated to research, clinical development, and commercialization.
Top Products and Market Share
Key Offerings
- STK-001: An antisense oligonucleotide being developed for the treatment of Dravet syndrome. It aims to increase the expression of the SCN1A protein. Currently in clinical development. Market share is not applicable, as it is still in development. Competitors in Dravet syndrome treatment include Zogenix (acquired by UCB), GW Pharmaceuticals (acquired by Jazz Pharmaceuticals), and Biocodex with treatments focusing on symptom management.
Market Dynamics
Industry Overview
The industry is the RNA therapeutics market, characterized by rapid growth and innovation, with increased investment and regulatory approvals. Driven by advances in understanding RNA biology and delivery technologies.
Positioning
Stoke is positioned as a leader in developing ASO-based therapies for genetic diseases, particularly focusing on upregulating gene expression. Their TANGO platform gives them a competitive edge in target discovery.
Total Addressable Market (TAM)
The RNA therapeutics market is projected to reach billions of dollars. Stoke's initial focus on Dravet syndrome represents a significant market opportunity, with potential expansion to other genetic diseases.
Upturn SWOT Analysis
Strengths
- Novel TANGO platform
- Focus on underserved genetic diseases
- Strong intellectual property position
- Experienced leadership team
Weaknesses
- Reliance on a single lead candidate
- High R&D expenses
- Clinical trial risks
- No currently marketed products
Opportunities
- Expanding the TANGO platform to new targets
- Partnerships and collaborations
- Positive clinical trial results
- Regulatory approvals
Threats
- Competition from other RNA therapeutics companies
- Clinical trial failures
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- IONS
- MRNA
- CRSP
Competitive Landscape
Stoke's advantage lies in its TANGO platform and focus on upregulating gene expression. Compared to larger companies like Ionis and Moderna, Stoke is a smaller player with a narrower focus. The competitive landscape is crowded but rapidly growing.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily driven by the advancement of their clinical programs and the expansion of the TANGO platform. Stock performance varies widely depending on clinical trial results.
Future Projections: Future growth depends on successful clinical trials and regulatory approvals for STK-001 and other pipeline candidates. Analyst estimates vary depending on the probability of success for these programs.
Recent Initiatives: Recent initiatives include advancing STK-001 in clinical trials, expanding the TANGO platform, and forging strategic partnerships.
Summary
Stoke Therapeutics is a clinical-stage biotechnology company with a novel platform for addressing genetic diseases by upregulating gene expression. Its lead candidate, STK-001, targets Dravet syndrome and is currently in clinical trials. The company's success hinges on the outcome of these trials and its ability to expand its pipeline. Stoke's financial health and clinical trial execution will be critical factors for its future growth. They need to look out for competition from larger companies with marketed products.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Stoke Therapeutics Inc. website
- SEC filings
- Analyst reports (e.g., from Yahoo Finance, Bloomberg)
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is based on general industry reports and may not be specific to Stoke's particular segment. Clinical trial outcomes are inherently uncertain.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Stoke Therapeutics Inc
Exchange NASDAQ | Headquaters Bedford, MA, United States | ||
IPO Launch date 2019-06-19 | Interim CEO & Director Mr. Ian F. Smith A.C.A., C.P.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 128 | |
Full time employees 128 | |||
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.